McKesson (MCK) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $9.93
- Estimate
- $9.54
- Surprise
- +4.1%
- Revenue (period 2026-06-30)
- $105.38B
- Score today
- 4.9/10
Revenue source: xbrl.
How the report landed
McKesson (MCK) beat the $9.54 estimate with adjusted EPS of $9.93 — a clear 4.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MCK Sell at 4.9/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +4.1% surprise compares with a +3.7% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Target reached (-11.5% upside)
- Quality below floor (3.5 < 4.0)
- Value-trap signals (3/5): Margin compression (op margin -15.5%), Material insider selling (25 sells, 0.07% of cap), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $992.87
- Stop
- $949.03
The stock trades at 26.6× trailing but 19.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 71 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
MCK at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Distribution
- Market cap
- $115.76B
- P/E (fwd)
- 19.6
- P/E (ttm)
- 26.6
- 52-week range
- $723.68–$1030.27
- Off 52-week high
- 3.6%
- RSI (14)
- 71
- Volume vs avg
- 0.72×
- Score today
- 4.9/10